Adjuvant chemo: no benefit if ovarian reserve is low

Editor's Pick: Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) (Annals of Oncology, 2026)
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning long-term outcomes and biomarker refinement in hormone-driven cancers, resistance and new drug platforms in oncogene-driven lung cancer, chemotherapy-free strategies in lymphoma, and a cluster of papers about drug safety and how we read so-called negative trials. Let's dive in.
This week's papers:
• Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42607282)
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2 — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42607281)
• EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42599162)
• Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304) — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42607762)
• Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive, HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42613139)
• Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42612796)
• Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42600120)
• BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42599166)
• SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42594871)
• A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42599167)
Listen at AudioScholar (audioscholar.cc/episode/ef9htvxqas)